[ad_1]
→ The Next Big Crisis Is Here (From Porter & Company)
Johnson & Johnson (NYSE:JNJ – Get Rating) – Equities research analysts at SVB Leerink upped their Q1 2023 EPS estimates for shares of Johnson & Johnson in a note issued to investors on Wednesday, January 25th. SVB Leerink analyst D. Risinger now forecasts that the company will earn $2.53 per share for the quarter, up from their previous estimate of $2.47. SVB Leerink has a “Outperform” rating and a $186.00 price objective on the stock. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.65 per share. SVB Leerink also issued estimates for Johnson & Johnson’s Q2 2023 earnings at $2.59 EPS, Q3 2023 earnings at $2.80 EPS, Q4 2023 earnings at $2.69 EPS, FY2023 earnings at $10.61 EPS, Q3 2024 earnings at $2.94 EPS, Q4 2024 earnings at $2.87 EPS, FY2024 earnings at $10.92 EPS, FY2025 earnings at $11.35 EPS and FY2026 earnings at $11.92 EPS.
Other equities analysts have also recently issued research reports about the stock. Raymond James lowered their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Sanford C. Bernstein lowered their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Atlantic Securities increased their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave a ut “ral stock ” rating in a research note on Wednesday. Bank of America lowered their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Finally, StockNews. com began coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Seven equities research analysts have rated the s tock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $182.75 .
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $168.89 on Friday. The firm’s 50-day moving average price is $175.90 and its 200-day moving average price is $171.04. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to -equity ratio of 0.37. The company has a market cap of $441.56 billion, a PE ratio of 25.06, a PEG ratio of 2.99 and a beta of 0.56. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.9 % and a return on equity of 35.94%. The company had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. During the same period in the prior year, the firm posted $2.13 EPS. Johnson & Johnson’s revenue for The quarter was down 4.4% on a year-over-year basis.
Institutional Trading of Johnson & Johnson
Several institutional investors and hedge funds have recently made changes to their positions in JNJ. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.2% in the third quarter. purchasing an additional 2,815,655 shares in the last quarter. State Street Corp grew its stake in shares of Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after acquiring an additional 803,013 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after 8 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Johnson & Johnson by 2.3% during the second qua rter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after acquiring an additional 421,779 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EEVP. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the sale, the executive own vice irly president now 71,311 shares in the company, valued at $12,366,753.62. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares of the stock company’s , valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock valued at $40,960,735 over the last three months. 0.35% of the stock is owned by company insiders.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield% of 2.68 The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.
Johnson & Johnson Company Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story contact@marketbeat.com.
Before you consider Johnson & Johnson, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.
While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
[ad_2]
Source link